NeuroTherapia has secured USD 12.3 million in the first closing of its Series B funding round, led by Cleveland Clinic. Existing investors Brain Trust Accelerator Fund II, Dolby Family Ventures, and the Alzheimer's Drug Discovery Foundation participated, along with new investors Foundation for a Better World and CRUINT.

The funds are expected to be used for the ongoing clinical development of NTRX-07, an oral treatment for Alzheimer's disease. The company also plans to raise additional funds within the next six months for its second close, which will support the development of a recently discovered second-generation molecule targeting a different indication where neuroinflammation is a key factor.

NeuroTherapia is a clinical-stage company developing new treatments for neuroinflammatory disorders. The company’s lead product, NTRX-07, is a highly selective cannabinoid type 2 (CB2) receptor agonist with demonstrated CNS activity that targets CB2 receptors on microglia. It significantly reduces the expression of inflammatory agents, resulting in neuronal survival and activation.

Analyst QuickTake: In October 2023, NeuroTherapia showed promising results in its Phase Ib trial , demonstrating cognitive benefits for Alzheimer's patients. The study data showed a favorable safety profile across all dose ranges, a pharmacokinetic (PK) profile consistent with preclinical studies. They expected to support clinical activity and a trend toward cognitive improvement in Alzheimer's disease (AD) patients treated with NTRX-07.